Gemphire Therapeutics Inc (GEMP:NASDAQ) Investor Relations Material

Overview

Gemphire is a clinical-stage biopharmaceutical company that is dedicated to finding new ways to treat patients suffering from cardiometabolic disorders. Their main focus is on developing a product candidate called gemcabene, which can be used in combination with standard treatments like statins to provide more effective relief. Their goal is to provide convenient and cost-effective treatment options for a wider range of patients, while also benefiting physicians and payors.

Frequently Asked Questions

What is Gemphire Therapeutics Inc's ticker?

Gemphire Therapeutics Inc's ticker is GEMP

What exchange is Gemphire Therapeutics Inc traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Gemphire Therapeutics Inc's headquarters?

They are based in Livonia, Michigan

How many employees does Gemphire Therapeutics Inc have?

There are 11-50 employees working at Gemphire Therapeutics Inc

What is Gemphire Therapeutics Inc's website?

It is http://www.gemphire.com/

What type of sector is Gemphire Therapeutics Inc?

Gemphire Therapeutics Inc is in the Healthcare sector

What type of industry is Gemphire Therapeutics Inc?

Gemphire Therapeutics Inc is in the Biotechnology industry

Who are Gemphire Therapeutics Inc's peers and competitors?

The following five companies are Gemphire Therapeutics Inc's industry peers:

- StrongPoint

- Dicerna Pharmaceuticals

- Seres Therapeutics

- Sangamo Therapeutics

- Editas Medicine